These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 16850392)

  • 1. Biophysical comparability of the same protein from different manufacturers: a case study using Epoetin alfa from Epogen and Eprex.
    Deechongkit S; Aoki KH; Park SS; Kerwin BA
    J Pharm Sci; 2006 Sep; 95(9):1931-43. PubMed ID: 16850392
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Protein isolated from biopharmaceutical formulations cannot be used for comparative studies: Follow-up to "a case study using Epoetin Alfa from Epogen and EPREX".
    Heavner GA; Arakawa T; Philo JS; Calmann MA; Labrenz S
    J Pharm Sci; 2007 Dec; 96(12):3214-25. PubMed ID: 17721976
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of the pharmacokinetic and pharmacodynamic profiles of one US-marketed and two European-marketed epoetin alfas: a randomized prospective study.
    Lissy M; Ode M; Roth K
    Drugs R D; 2011; 11(1):61-75. PubMed ID: 21410296
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pure red-cell aplasia and epoetin therapy.
    Bennett CL; Luminari S; Nissenson AR; Tallman MS; Klinge SA; McWilliams N; McKoy JM; Kim B; Lyons EA; Trifilio SM; Raisch DW; Evens AM; Kuzel TM; Schumock GT; Belknap SM; Locatelli F; Rossert J; Casadevall N
    N Engl J Med; 2004 Sep; 351(14):1403-8. PubMed ID: 15459301
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The oxidation of methionine-54 of epoetinum alfa does not affect molecular structure or stability, but does decrease biological activity.
    Labrenz SR; Calmann MA; Heavner GA; Tolman G
    PDA J Pharm Sci Technol; 2008; 62(3):211-23. PubMed ID: 18661870
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Kinetic and thermodynamic analysis of thermal unfolding of recombinant erythropoietin.
    Arakawa T; Philo JS; Kita Y
    Biosci Biotechnol Biochem; 2001 Jun; 65(6):1321-7. PubMed ID: 11471731
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pure red cell aplasia with anti-erythropoietin antibodies occurs more commonly with one formulation of epoetin alfa than another.
    Macdougall IC
    Curr Med Res Opin; 2004 Jan; 20(1):83-6. PubMed ID: 14741076
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Micelle-associated protein in epoetin formulations: aA risk factor for immunogenicity?
    Hermeling S; Schellekens H; Crommelin DJ; Jiskoot W
    Pharm Res; 2003 Dec; 20(12):1903-7. PubMed ID: 14725351
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interaction of polysorbate 80 with erythropoietin: a case study in protein-surfactant interactions.
    Villalobos AP; Gunturi SR; Heavner GA
    Pharm Res; 2005 Jul; 22(7):1186-94. PubMed ID: 16028020
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biochemical assessment of erythropoietin products from Asia versus US Epoetin alfa manufactured by Amgen.
    Park SS; Park J; Ko J; Chen L; Meriage D; Crouse-Zeineddini J; Wong W; Kerwin BA
    J Pharm Sci; 2009 May; 98(5):1688-99. PubMed ID: 18781649
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-erythropoietin antibody-mediated pure red cell aplasia after treatment with recombinant erythropoietin products: recommendations for minimization of risk.
    Cournoyer D; Toffelmire EB; Wells GA; Barber DL; Barrett BJ; Delage R; Forrest DL; Gagnon RF; Harvey EA; Laneuville P; Patterson BJ; Poon MC; Posen GA; Messner HA;
    J Am Soc Nephrol; 2004 Oct; 15(10):2728-34. PubMed ID: 15466278
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Stability of multidose, preserved formulation epoetin alfa in syringes for three and six weeks.
    Naughton CA; Duppong LM; Forbes KD; Sehgal I
    Am J Health Syst Pharm; 2003 Mar; 60(5):464-8. PubMed ID: 12635452
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Physical and biophysical effects of polysorbate 20 and 80 on darbepoetin alfa.
    Deechongkit S; Wen J; Narhi LO; Jiang Y; Park SS; Kim J; Kerwin BA
    J Pharm Sci; 2009 Sep; 98(9):3200-17. PubMed ID: 19388064
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetic and Pharmacodynamic Equivalence of Epoetin Hospira and Epogen After Single Subcutaneous Doses to Healthy Male Subjects.
    Stalker D; Reid S; Ramaiya A; Wisemandle WA; Martin NE
    Clin Ther; 2016 Aug; 38(8):1778-88. PubMed ID: 27473384
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recognition and identification of UV-absorbing leachables in EPREX pre-filled syringes: an unexpected occurrence at a formulation-component interface.
    Pang J; Blanc T; Brown J; Labrenz S; Villalobos A; Depaolis A; Gunturi S; Grossman S; Lisi P; Heavner GA
    PDA J Pharm Sci Technol; 2007; 61(6):423-32. PubMed ID: 18410043
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of erythropoietin biosimilars Epotin™, Hemax® and Jimaixin™ by electrophoretic methods used for doping control analysis and specific N-glycan analysis revealed structural differences from original epoetin alfa drug Eprex®.
    Capdeville P; Martin L; Cholet S; Damont A; Audran M; Ericsson M; Fenaille F; Marchand A
    J Pharm Biomed Anal; 2021 Feb; 194():113750. PubMed ID: 33234415
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomized trial on the therapeutic equivalence between Eprex and GerEPO in patients on haemodialysis.
    Goh BL; Ong LM; Sivanandam S; Lim TO; Morad Z;
    Nephrology (Carlton); 2007 Oct; 12(5):431-6. PubMed ID: 17803464
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Quality and Batch-to-Batch Consistency of Original and Biosimilar Epoetin Products.
    Halim LA; Brinks V; Jiskoot W; Romeijn S; Haselberg R; Burns C; Wadhwa M; Schellekens H
    J Pharm Sci; 2016 Feb; 105(2):542-550. PubMed ID: 26869417
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epoetin alfa (Eprex) and quality of life.
    Littlewood T
    Curr Med Res Opin; 2005; 21 Suppl 2():S1-2. PubMed ID: 15969857
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.